BOVen: Zanubrutinib, Obinutuzumab, and Venetoclax Yields 75% OS at 2 Years in High-Risk MCL

In a packed session Monday at the 65th American Society of Hematology Annual Meeting and Exposition in San Diego, California, Anita Kumar, MD, of Memorial Sloan Kettering Cancer Center presented phase 2 results for 25 patients with TP53 mutations.

Related Keywords

New Jersey ,United States ,San Diego ,California ,Massachusetts ,American ,Anita Kumar ,American Society Of Hematology Annual Meeting ,Memorial Sloan Kettering Cancer Center ,International Prognostic Index ,New England Journal ,Massachusetts General Hospital ,American Society ,Hematology Annual Meeting ,Basking Ridge ,Prognostic Index ,Zanubrutinib ,Obinutuzumab ,Venetoclax ,Mantle Cell Lymphoma ,Aboven ,Btk Inhibitor ,Bcl2 Inhibitor ,Tp53 Mutation ,Memorial Sloan Kettering ,